Paraneoplastic cerebellar degeneration in a woman with ovarian cancer

Nature Clinical Practice Oncology

Volumn 3, Issue 2, 2006, Pages 108-112

  Santillan, Antonio ^a   Bristow, Robert E ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Anti yo antibody; Immune mediated; Ovarian Cancer; Paraneoplastic cerebellar degeneration; Paraneoplastic syndromes

Indexed keywords

CARBOPLATIN; CELL ANTIBODY; PACLITAXEL; TUMOR MARKER;

ADULT; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; BIOPSY; BRAIN; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; COLONOSCOPY; CYTOREDUCTIVE SURGERY; DIPLOPIA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DYSARTHRIA; ELECTROENCEPHALOGRAM; FEMALE; GAIT DISORDER; GYNECOLOGICAL EXAMINATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LAPAROSCOPY; LUMBAR PUNCTURE; LYMPH NODE DISSECTION; MAMMOGRAPHY; MONOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OMENTUM; OSCILLOPSIA; OVARY CARCINOMA; PARAAORTIC LYMPH NODE; PARANEOPLASTIC NEUROPATHY; PHYSICAL EXAMINATION; PLASMAPHERESIS; PLEOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPEECH THERAPY; TRANSVAGINAL ECHOGRAPHY; VERTIGO; VIRUS MENINGITIS; WHOLE BODY TOMOGRAPHY;

CARCINOMA, ENDOMETRIOID; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PARANEOPLASTIC CEREBELLAR DEGENERATION;

EID: 32844475151     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0379     Document Type: Article

References (16)

1. Posner JB (Ed.; 1995) Paraneoplastic syndromes. In Neurologic complications of cancer, 353-385 Philadelphia: Oxford University Press Inc.
2. Rojas I et al. (2000) Long-term clinical outcomes of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55: 713-715
3. Graus F et al. (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75: 1135-1140
4. Bolla L and Palmer RM (1997) Paraneoplastic cerebellar degeneration. Arch Intern Med 157: 1258-1262
5. Tanaka K et al. (1994) Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci 127: 153-158
6. Peterson K et al. (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42: 1931-1937
7. Liu SMJ et al. (1994) Expression of Purkinje cell antigens in ovarian tumor and the presence of anti-Purkinje cell antibodies in the serum of patients without paraneoplastic cerebellar degeneration. Neurology 45: A288-A229
8. Jacobs IJ et al. (1996) Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: A prospective cohort study. BMJ 313: 1355-1358
9. Jacobs I et al. (1990) A risk of malignancy index incorporating CA125, ultrasound and menopausal status after the accurate pre-operative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97: 922-929
10. Hogdall EV et al. (2000) Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 89: 519-523
11. Younes-Mhenni S et al. (2004) FDG-PET improves tumor detection in patients with paraneoplastic neurological syndromes. Brain 127: 2331-2338
12. Sutton I (2002) Paraneoplastic neurological syndromes. Curr Opin Neurol 15: 685-690
13. Bristow RE et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era; a meta-analysis. J Clin Oncol 20: 1248-1259
14. Cao Y et al. (1999) Anti-Yo-positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: Case report and review of the literature. Gynecol Oncol 75: 178-183
15. Darnell RB and Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349: 1543-1554
16. Perlmutter E and Gregory PC (2003) Rehabilitation treatment options for a patient with paraneoplastic cerebellar degeneration. Am J Phys Med Rehabil 82: 158-162